Skip to main content

Impact of pain severity on functioning domains, sleep, and cognition in painful diabetic peripheral polyneuropathy patients

Abstract

Background

Several studies have observed that painful diabetic peripheral polyneuropathy (PDPN) had an impact on the level of functioning domains and quality of sleep as well as cognitive functions. This study is aimed to explore the relationship between severity of pain and level of functioning, sleep quality, and cognitive functions among these patients. We recruited 100 diabetics with a mean HbA1C% of 7.3±0.9, diagnosed with PDPN, and included in the study with a mean age of 51±12.8 years and disease duration of 10.2±7.4 years. The following assessment was done for each patient; clinical and neurophysiology assessment, routine laboratory assessment, measuring pain severity, and average pain severity interference scores using pain visual analog scale (VAS) and brief pain inventory (BPI) short form, respectively, sleep quality assessment using Pittsburgh Sleep Quality Index (PSQI) and Montreal cognitive function assessment (MOCA) scales.

Results

Moderate to severe pain was recorded in 71% of patients according to the VAS pain score. The severe pain group recorded the significant highest average pain severity and interference scores in BPI and domains compared to other less pain groups with average pain intensity scores of 7.5±0.6 vs 5.3±0.8 in the moderate and 3.3±0.4 in mild pain groups. Poor sleep quality and pattern were observed in these patients with a mean PSQI score of 6.8±3.1, and the severe pain group had a significant highest score of 9.4±2.3 compared to other less group scores of 7±2.3 and 3.7±1.8. Their mean MOCA score was low 24.2±2.2. Out of them 48/100 patients had mild cognitive impairment and recorded high frequency in the severe pain group (28/32) followed by the moderate pain (15/39) group. There is a significant correlation between the score of VAS and PSQI as well as MOCA.

Conclusions

Painful DPN patients had a poor level of functioning and sleep quality as well as cognitive impairment based on pain intensity.

Trial registration

This study was registered on a clinical trial with registration number NCT03275233 on 7 September 2017.

Background

The International Diabetes Federation (IDF) reports have stated that more than 436 million people have diabetes [1, 2]. Distal symmetrical polyneuropathy (DPN) is the most prevalent diabetic neuropathy and is recorded in up to 50% of diabetics. According to the American Diabetes Association Position Statement, DPN is defined as “the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes [3].

DPN is a major morbidity, causing non-traumatic amputations [4]. Patients with painful DPN (PDPN) reported in their complaints a stinging, burning, and keen sensation that increases at night with a loss of sensation or numbness of the involved area [5, 6].

The intensity of neuropathic pain is variable in PDPN. PDPN is observed in different clinical syndromes, and mixed large and small fiber neuropathy is the most common [7].

There are evidences suggesting the association between chronic pain and sleep [8]. However, other studies used different methods in analyzing these processes and findings, making comparisons difficult [9]. Moreover, sleep disturbances as a common squeal can affect cognitive function [10] that may explain cognitive function deterioration in these patients [11]. That could be explained by pain pathophysiology and different underlying neurobiological mechanisms [12]. So, PDPN had an impact on the quality of life of these patients and a broad financial burden [13].

This study is aimed to determine the impact of pain severity on functioning domains in patients’ life with PDPN, sleep quality, and cognitive functions as well as the possible relationship between scores of VAS pain and used clinical rating scales.

Methods

This descriptive cross-sectional study was conducted over a 6-month duration elapsed from the 1st of September 2019 to the 29th of February 2020 in the neurology outpatients clinic at the Neuropsychiatry Department, in Assiut University Hospital. One hundred fifty recruited diabetic patients presenting with painful distal sensorimotor polyneuropathy were met the eligibility criteria for PDPN and included in the study.

The inclusion criteria were as follows: (a) Any type II diabetic patient, aged 18 years or more, was diagnosed as a diabetic distal symmetrical sensorimotor polyneuropathy or other subtypes of diabetic neuropathy associated with painful symptoms (i.e., burning, prickling, tingling, and/or shooting pain in the toes, feet, legs, and/or hands) of at least 3-month duration since the date of diagnosis of symptomatic (painful) diabetic neuropathy and (b) able to give consent for the participation in the study and providing personal medical and clinical data.

The exclusion criteria were as follows: (a) any patient with comorbid significant medical and neurological disorders or (b) patients with severe mental illness that may interfere with the study variables or (c) a patient with severe motor weakness was also excluded from the study.

All patients who participated in the study did not receive any specific medical treatment for pain either pain killer or anti-depressant. They are novel assessed for pain in this study.

We excluded fifty patients from the study who met the exclusion criteria as follows: twenty patients had serious unstable comorbid medical conditions (seventeen patients had uncontrolled hypertension, out of them five had renal insufficiency, and three patients had refractory heart failure), two patients had comorbid mood disorders, ten patients had previous stroke, one patient had a lumbar disc, four patients had chronic ischemia of the lower limbs, eight patients had uncontrolled diabetes and frequent diabetic coma, and five patients refused the participation in the study or do neurophysiology to confirm the diagnosis.

Ethics

This study had ethical approval from the Institutional Review Board (IRB) of the Faculty of Medicine, Assiut University, with an approval number (IRB17100291). This study was registered on a clinical trial with registration number NCT03275233, https:// clinical trials.gov/ct2/show/NCT03275233 in September 2017.

All eligible patients gave informed consent for participation in the study after the approval of the Ethical Committee of the Faculty of Medicine, Assiut University.

Study design

One hundred eligible patients were conducted with nerve conduction study to confirm the diagnosis of PDPN and underwent the following: (1) history case-taking, clinical and neurological assessment including the onset of DM and treatment; (2) cardiac assessment and ECG; (3) laboratory investigation, i.e., HbA1c%, serum urea, and creatinine; and (4) the following clinical rating scales.

Pain visual analog scale (VAS) [14]

It is a self-reported 10-cm visual analog scale (VAS) used for the pain intensity assessment by the subjects where “0” means no pain and “10” shows unbearable severe pain. VAS pain scores among these patients ranged from 3 to 8, so the pain severity is classified into mild (3), moderate (4–6), and severe (≥7) pain suffers.

Brief pain inventory (short form) for measuring average pain intensity score and pain interference scores [15]

It is a self-reported nine-item scale measuring the average intensity of pain and the interference of pain on patient functioning domains. The mean of items 3–6 measures the pain severity score. BPI average pain intensity score was ≥3 among these patients. The mean of items 9A–9G measures the average pain interference scores, i.e., the interference of the pain with the following aspects: general activity, mood, walking, normal work, relations with other people, sleep, and enjoyment of life). The BPI assessed the pain intensity score in the past 24 h and the severity of the pain right now. Outcomes for each item range from 0 (no) to 10 (bad). The BPI interference pain score with the patient’s functioning in the past 24 h is ranged from 0 to10; 0=no interference and 10 =complete interference.

The Pittsburgh Sleep Quality Index (PSQI) [16] for the assessment of the sleep quality and pattern

It is a self-rated questionnaire, assessing the sleep quality and disturbances over a 1-month time interval. It is nineteen individual items and generates seven “component” scores, i.e., subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of the seven-component scores yields one global score. A total score of “5” or more is indicating poor sleep quality [16].

Montreal Cognitive Assessment (MOCA) [17]

MOCA is a 30-point test assessing the following domain; memory recall, visuospatial abilities, attention and concentration, language, abstraction, calculation, and orientation. MOCA score <26 is indicating cognitive impairment.

Statistical analysis

For the statistical analysis, SPSS-version 16 software was used. Data was expressed as the number and percentage or mean± standard deviation (SD). Chi-square test was used to compare proportions. One-way ANOVA was used for comparison between the three groups of the numeric data. Pearson’s correlations were done between pain VAS score and demographics as well as clinical rating scales scores. Results were considered significant if P <0.05.

Result

Sociodemographic and clinical data

The mean age of the studied patients was 51±12.8 years old with a range of 22–74 years. In the studied sample, the male sex (55%) and rural residents (59%) were predominant. The majority of the studied cases (62%) were illiterate. Among these patients, the mean duration of DM was 10.2±7.4 years, and the mean HbA1c% was 7.3±0.9.

Based on the VAS pain score, 71% of patients had moderate to severe pain: the pain was recorded as follows: severe in 32 patients, moderate in 39 patients, and mild pain in the remaining (n=29) patients. The severe pain group was the oldest one compared to the mean age of other less pain groups [54.2±13.2 vs 52.5±11.7 vs 45.5±12.4 years], p>0.05. Illiteracy and low education were observed in high frequency among the severe pain group (29/32) compared to other less pain groups (23/32 & 10/29), p<0.05. Concerning glycemic control, a significant high mean HbA1c% was observed among the severe pain group compared to the mean HbA1c% of other less pain groups (8.3±0.5 vs 7.2±0.3 in moderate pain and 6.3±0.2 in the mild pain groups, p=0.0001). No observed significant difference was found in other demographic or clinical data between different pain groups (see Table 1).

Table 1 Demographic and clinical data of PDPN patients among different pain severity groups

Brief pain inventory (BPI) results were revealing that studied patients recorded an average pain severity score of 5.4 ± 1.8 and a high average interference pain score of 5.6±1.7. Also among studied patients, the average interference pain score to functioning domains was high, the general activity was 6.3±2.1, the mood was 5.6±2, the walking ability was 5.9±2.1, the normal walking was 5.8±2, the relation with other people was 3.8±1.7, sleep was 5.3±1.8, and the enjoyment of life was 5.1±1. A significant high average pain severity score of 7.5±0.6 was recorded in the severe pain group compared to the average score in other less pain groups, 5.3±0.8 in moderate pain, 3.3±0.4 in mild pain, and p=0.0001. The same was recorded in the average pain interference score and average interference pain score for all functioning domains related to BPI, p=0.0001 for all (see Table 2).

Table 2 Mean value ± SD of average pain severity, interference pain scores, and functioning domain scores in BPI among different pain severity groups

On the assessment of the sleep quality and pattern in these patients using PSQI, we found that poor sleep quality and pattern were observed in them with a mean total PSQI score of 6.8±3.1, and the severe pain group had the significant highest PSQI score of 9.4±2.3 compared to other less pain groups [7±2.3 in moderate pain and 3.7±1.8 in mild pain], p=0.0001. The same was observed in all sleep component scores apart from C4 habitual sleep efficiency (see Table 3).

Table 3 Mean value score± SD of total PSQI and component scale among different pain severity groups

On cognitive function assessment of these patients using the MOCA scale, we found that their mean MOCA score was low 24.2±2.2. Out of them, 48/100 patients had mild cognitive impairment with the recorded high frequency of severe pain (28/32) followed by the moderate pain (15/39) group and the least frequency in the mild group 3/29, p=0.0001.

There was a significant correlation was found between VAS pain score and age (r=0.283, p=0.004) as well as serum HbA1c% (r=0.909, p=0.0001) using Pearson correlation. A significant positive correlation was observed between the VAS pain score and average interference pain score as well as the average interference pain score to all functioning domain scores related to (9A–9G items) BPI (r=0.988, 0.952, 0.903, 0.892, 0.912, 0.884, 0.797, 0.883, and 0.864, respectively, to these (9A–9G items) domains, p=0.0001 for all). Also there is a significant correlation between VAS pain score and PSQI score (r=0.771, p=0.0001) and MOCA score (r= −0624; p=0.0001).

Discussion

The present study is conducted on 100 PDPN patients to determine the impact of the pain severity on PDPN patients’ functioning domains, sleep quality and cognitive functions, and the relationship between VAS pain score and clinical rating scale scores on the one hand and demographics of PDPN patients and their clinical data on the other hand.

More than two thirds of the studied patients were suffering from moderate to severe pain based on the VAS pain score, and the severe pain group was the oldest group. Moreover, age had a significant positive association with the VAS pain score (p<0.01). Our data are consistent with many studies that reported age as a risk factor for pain among PDPN patients [18,19,20,21,22,23], while few studies have shown no association [24].

Concerning sex predisposition, males are higher in frequency (55%) than females (45%) without a significant difference or association among studied PDPN patients. These data are consistent with the reported data of men who had been at higher risk than women for PDPN development in diabetes [25], while the observed female preponderance was found in another study [26]. In this study, no sex predisposition for PDPN severity was observed (p>0.05). The present observation was supported by others who reported no sex difference [27]. However, other studies were retrospectively observed that men had early onset of diabetic neuropathy that may be attributed to their exposure to more hazardous than women in lifestyle [28, 29].

Concerning other demographic data in our study among PDPN patients, we found that 94% were married, only 38% were educated, and 61% were not working, which indicate a low socioeconomic state. Moreover, 59% were rural residents. These data are matched with the observed protective effect of marriage, high educational level, and family income, as it is consistent with the studies’ results that the link between better health care and self-care knowledge and practice with higher educational and family income levels [30, 31]. Moreover, the marriage may buffer against stress and thereby reduce the activation of the neuroendocrine system [32]. In our study, no relationship was found between PDPN and smoking (p>0.05). However, cigarette smoking was found to be associated with an increased risk of PDPN in other studies [33, 34]. These different data in this study could be attributed to patients with vascular complications or other causes attributed to DPN that were excluded, whereas different studies’ findings could be attributed to the criteria of the selected patients and study designs as well as the used tools in different studies.

In this study, the majority of severe pain (81.2%) in PDPN patients suffered from DM of about 6 years or more. Moreover, a positive association was found between PDPN pain score and DM duration (p>0.05). However, others reported that DM duration is a risk factor for the development of PDPN [35,36,37,38].

Based on HbA1c%, the studied PDPN patients had poor glycemic control and showed a significant correlation between HbA1c% and VAS pain score (p<0.0001). In another study, it was observed that glycemic control over time was significantly worse in those with PDPN compared with no PDPN [39]. Moreover, good glycemic control could potentially delay PDPN development and progression as well as other microvascular complications in different DM types, T1D and T2D [40, 41]. Inflammation and dysfunction of the endoneural, perineurial, and epineural blood vessels are leading to axonal atrophy, degeneration, and impaired axonal transport as well as contributing to functional and structural abnormalities in PDPN [42]. Thus, good glycemic control in these patients could go a long way in preventing or delaying the development of PDPN; however, others observed a lack of association between PDPN and HbA1c% [35, 43].

Based on the VAS pain score, we found that 29 patients had mild pain, 39 patients had moderate pain, and 32 patients had severe pain. Among these pain severity groups, BPI data is revealing that these studied patients assuming average pain severity scores of ≥4 are indicative of considerable daily suffering [44, 45] and experienced substantial pain (see Table 2). Our results about the average pain experience severity score among these patients have been found to be higher than others [46,47,48]. It may be related to the low socioeconomic state and educational level of our patients with PDPN. Moreover, according to the average interference pain score in functioning domains of BPI, chronic pain restricts a patient’s performance in daily activities of functioning domains, causing a negative impact on their functioning domains including the general activity, mood, walking ability, normal walk, relation with other people, sleep, and enjoyment of life as the average interference pain score for all patients was >4 (5.6±1.7) and the average interference pain scores in different domains were >3 in the studied patients ranged from 3.8±1.7 in an average interference pain score in relation with other people’s domain to 6.3±2.1 in the interference pain score to the general activity domain, as the majority of domains recorded the interference pain score of > 4 (see the “Results” section). Furthermore, patients in this study experienced a significantly high substantial average PDPN pain-related interference score (≥4) in functioning domains of patients’ life in the severe pain group compared to the moderate and mild pain groups (see Table 2). Moreover, their reported scores were higher than the reported pain functional interference scores of other studies [47, 49]. However, our results of high average BPI score are consistent with the results of BPI of another study [50]. Moreover in our study, there is a strong significant positive correlation between the VAS pain score and average pain severity score and the pain interference score in all these functioning domains in BPI (p<0.0001).

Concerning the sleep quality and pattern that were measured by Pittsburgh sleep quality index PSQI, it was observed that cases with a sleep disturbance and poor sleep quality, whose scores are >5 in PSQI [51]. These studied patients recorded a high mean score of PSQI (6.8±3.1), indicating that PDPN patients had a significant poor sleep quality among different pain severity groups in PDPN patients. Moreover, the highest recorded score was 9.4±2.3 among the severe pain group compared to other less pain groups, p<0.0001(see Table 3). The prevalence rate of sleep disturbances in these PDPN patients was 86%. It is consistent with various researches on chronic pain found that sleep disturbance rate range between 50 and 80% [52, 53]. Our recorded prevalence rate is similar to the Iranian prevalence rate (85.5%). Moreover, Gore et al.’s screening study reported that the subjects with PDPN have greater sleep problems compared with the general US population using the medical outcome of the study sleep problem (MOS sleep scale), as their mean overall sleep index score was 47.1 PDPN versus 25.8 population norm score [48]. Also, others using the MOS sleep scale found that patients with PDPN had a substantially higher overall score of 48.5, ranged from mild to severe sleep problems, which indicate worse sleep outcomes [54]. Furthermore, in our study, there is a significant positive correlation between the VAS pain sore and PSQI score regarding all components of the PSQI questionnaire (p<0.0001).

Nearly half of the total PDPN patients had a mild cognitive impairment (MOCA score<26), and the highest frequency was recorded among the severe pain group compared to other less pain groups, p<0.0001. The same was found in other studies [11, 55, 56]. However, this deterioration in cognitive function may be attributed to central microangiopathy in DM associated with poor glycemic control among PDPN patients. These patients have been investigated in many studies and showed thalamic neuronal dysfunction and perfusion abnormalities in MRI studies and somatosensory afferent pathway dysfunctions in evoked potential studies [57,58,59]. So, these data are suggesting a connection between cognitive dysfunction and PDPN in diabetics, as some similarities in the pathogenic mechanisms of both cognitive dysfunction and PDPN development were observed regarding common predisposing risk factors for both such as chronic hyperglycemia and HAlb1c% levels [60]. This cognitive deterioration in diabetics has been established by others [61]. Moreover, in this study, we found that there is a significant negative correlation between VAS pain score and MOCA score (p<0.0001). This association was found by others [11, 56]. Thus, diabetes and chronic pain may explain and consider cognitive dysfunction as observed complications in PDNP patients [56].

Conclusions

In summary, PDPN patients have significant impairment of functioning domains as well as sleep disturbance associated with longer sleep latency duration and cognitive impairment. These findings are based on pain severity among these patients and glycemic control.

Study limitations

Important limitations of this study are the relative small sample size and lack of follow-up of these patients after the management of neuropathic pain using the same rating scales for measuring outcomes on their quality of functioning level in life domains, sleep pattern, and cognitive functions.

Availability of data and materials

All data generated or analyzed during this study are available from the corresponding author upon request.

Abbreviations

PDPN:

Painful diabetic peripheral polyneuropathy

VAS:

Visual analog scale

BPI:

Brief pain inventory

PSQI:

Pittsburgh Sleep Quality Index

MOCA:

Montreal cognitive function assessment scale

DPN:

Distal symmetrical polyneuropathy

ECG:

Electrocardiogram

DM:

Diabetes mellitus

IDP:

The International Diabetes Federation

T1D and T2D:

Type I DM and type II DM

MOS sleep scale:

Medical outcome study for sleep scale

References

  1. Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW et al (2020) Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 162:108086

    PubMed  Article  Google Scholar 

  2. Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besançon S et al (2020) Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 162:108072

    PubMed  Article  Google Scholar 

  3. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA et al (2017) Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care 40(1):136–154

    CAS  PubMed  Article  Google Scholar 

  4. Narres M, Kvitkina T, Claessen H, Droste S, Schuster B, Morbach S et al (2017) Incidence of lower extremity amputations in the diabetic compared with the non-diabetic population: a systematic review. PLoS One 12(8):e0182081

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  5. Balhara YPS, Singh S, Kalra S (2020) Pragmatic opioid use in painful diabetic neuropathy. Eur Endocrinol 16(1):21–24

    PubMed  PubMed Central  Article  Google Scholar 

  6. Sloan G, Shillo P, Selvarajah D, Wu J, Wilkinson ID, Tracey I et al (2018) A new look at painful diabetic neuropathy. Diabetes Res Clin Pract 144:177–191

    PubMed  Article  Google Scholar 

  7. Shillo P, Sloan G, Greig M, Hunt L, Selvarajah D, Elliott J et al (2019) Painful and painless diabetic neuropathies: what is the difference? Curr Diabetes Rep 19(6):32

    Article  Google Scholar 

  8. Senba E (2015) A key to dissect the triad of insomnia, chronic pain, and depression. Neurosci Lett 589:197–199

    CAS  PubMed  Article  Google Scholar 

  9. Naranjo C, Dueñas M, Barrera C, Moratalla G, Failde I (2020) Sleep characteristics in diabetic patients depending on the occurrence of neuropathic pain and related factors. Int J Environ Res Public Health 17(21):8125

    CAS  PubMed Central  Article  Google Scholar 

  10. O'Brien EM, Waxenberg LB, Atchison JW, Gremillion HA, Staud RM, McCrae CS et al (2011) Intraindividual variability in daily sleep and pain ratings among chronic pain patients: bidirectional association and the role of negative mood. Clin J Pain 27(5):425–433

    PubMed  Article  Google Scholar 

  11. Ojeda B, Dueñas M, Salazar A, Mico JA, Torres LM, Failde I (2018) Factors influencing cognitive impairment in neuropathic and musculoskeletal pain and fibromyalgia. Pain Med (Malden, Mass) 19(3):499–510

    Article  Google Scholar 

  12. Baron R, Maier C, Attal N, Binder A, Bouhassira D, Cruccu G et al (2017) Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain. 158(2):261

    PubMed  Article  Google Scholar 

  13. Gregory NS, Seley JJ, Dargar SK, Galla N, Gerber LM, Lee JI (2018) Strategies to prevent readmission in high-risk patients with diabetes: the importance of an interdisciplinary approach. Curr Diabetes Rep 18(8):1–7

    Article  Google Scholar 

  14. Price DD, McGrath PA, Rafii A, Buckingham B (1983) The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 17(1):45–56

    PubMed  Article  Google Scholar 

  15. Cleeland CS (1989) Measurement of pain by subjective report. Adv Pain Res Ther 12:391–403

    Google Scholar 

  16. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213

    CAS  PubMed  Article  Google Scholar 

  17. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699

    PubMed  Article  Google Scholar 

  18. Rani PK, Raman R, Rachapalli SR, Pal SS, Kulothungan V, Sharma T (2010) Prevalence and risk factors for severity of diabetic neuropathy in type 2 diabetes mellitus. Indian J Med Sci 64(2):51–57

    PubMed  Article  Google Scholar 

  19. Al Ani YA (2011) Predicting microvascular complications in diabetic patients. Iraqi. J Med Sci 9(3)

  20. Lu B, Yang Z, Wang M, Yang Z, Gong W, Yang Y et al (2010) High prevalence of diabetic neuropathy in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract 88(3):289–294

    PubMed  Article  Google Scholar 

  21. Kasim K, Amar M, El Sadek AA, Gawad SA (2010) Peripheral neuropathy in type-II diabetic patients attending diabetic clinics in Al-Azhar University Hospitals, Egypt. Int J Diabetes Mellitus 2(1):20–23

    Article  Google Scholar 

  22. Fedele D, Comi G, Coscelli C, Cucinotta D, Feldman EL, Ghirlanda G et al (1997) A multicenter study on the prevalence of diabetic neuropathy in Italy. Diabetes Care 20(5):836–843

    CAS  PubMed  Article  Google Scholar 

  23. Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M et al (2004) Prevalence of lower-extremity disease in the US adult population≥ 40 years of age with and without diabetes: 1999–2000 national health and nutrition examination survey. Diabetes Care 27(7):1591–1597

    PubMed  Article  Google Scholar 

  24. Shaw JE, Hodge AM, De Courten M, Dowse GK, Gareeboo H, Tuomilehto J et al (1998) Diabetic neuropathy in Mauritius: prevalence and risk factors. Diabetes Res Clin Pract 42(2):131–139

    CAS  PubMed  Article  Google Scholar 

  25. Group DR (1988) Factors in development of diabetic neuropathy: baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). Diabetes. 37(4):476–481

    Article  Google Scholar 

  26. Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MR, Matthews DR (2012) The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr 4(1):1–8

    Article  Google Scholar 

  27. Gregersen G (1967) Diabetic neuropathy: influence of age, sex, metabolic control, and duration of diabetes on motor conduction velocity. Neurology. 17(10):972

    CAS  PubMed  Article  Google Scholar 

  28. Aaberg ML, Burch DM, Hud ZR, Zacharias MP (2008) Gender differences in the onset of diabetic neuropathy. J Diabetes Complicat 22(2):83–87

    Article  Google Scholar 

  29. Kamenov ZA, Parapunova RA, Georgieva RT (2010) Earlier development of diabetic neuropathy in men than in women with type 2 diabetes mellitus. Gender Med 7(6):600–615

    Article  Google Scholar 

  30. Çaliskan D, Ozdemir O, Ocaktan E, Idil A (2006) Evaluation of awareness of diabetes mellitus and associated factors in four health center areas. Patient Educ Couns 62(1):142–147

    PubMed  Article  Google Scholar 

  31. Sturm R, Gresenz CR (2002) Relations of income inequality and family income to chronic medical conditions and mental health disorders: national survey. BMJ 324(7328):20

    PubMed  PubMed Central  Article  Google Scholar 

  32. Ikeda A, Iso H, Toyoshima H, Fujino Y, Mizoue T, Yoshimura T et al (2007) Marital status and mortality among Japanese men and women: the Japan Collaborative Cohort Study. BMC Public Health 7(1):1–7

    Article  Google Scholar 

  33. Barbosa A, Medina J, Ramos E, Barros H (2001) Prevalence and risk factors of clinical diabetic polyneuropathy in a Portuguese primary health care population. Diabetes Metab 27(4 Pt 1):496–502

    CAS  PubMed  Google Scholar 

  34. Eliasson B (2003) Cigarette smoking and diabetes. Prog Cardiovasc Dis 45(5):405–413

    CAS  PubMed  Article  Google Scholar 

  35. Khawaja N, Abu-Shennar J, Saleh M, Dahbour SS, Khader YS, Ajlouni KM (2018) The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan. Diabetol Metab Syndr 10(1):1–10

    Article  CAS  Google Scholar 

  36. Al-Kaabi JM, Al Maskari F, Zoubeidi T, Abdulle A, Shah SM, Cragg P et al (2014) Prevalence and determinants of peripheral neuropathy in patients with type 2 diabetes attending a tertiary care center in the United Arab Emirates. J Diabetes Metab 5(346):2

    Google Scholar 

  37. Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A (2014) Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig 5(6):714–721

    PubMed  PubMed Central  Article  Google Scholar 

  38. Pop-Busui R, Lu J, Lopes N, Jones TL (2009) Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst 14(1):1–13

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. Jaiswal M, Divers J, Dabelea D, Isom S, Bell RA, Martin CL et al (2017) Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. Diabetes Care 40(9):1226–1232

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. Control D, Group CTR (1994) Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. Diabetes Control and Complications Trial Research Group. J Pediatr 125:177–188

    Article  Google Scholar 

  41. Group UPDS (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853

    Article  Google Scholar 

  42. Cameron NE, Eaton S, Cotter MA, Tesfaye S (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 44(11):1973–1988

    CAS  PubMed  Article  Google Scholar 

  43. Won J, Kwon H, Kim C, Lee J, Park T, Ko K et al (2012) Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with type 2 diabetes in Korea. Diabet Med 29(9):e290–e2e6

    CAS  PubMed  Article  Google Scholar 

  44. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M (2005) Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain. 115(1-2):29–36

    PubMed  Article  Google Scholar 

  45. Zelman DC, Hoffman DL, Seifeldin R, Dukes EM (2003) Development of a metric for a day of manageable pain control: derivation of pain severity cut-points for low back pain and osteoarthritis. Pain. 106(1-2):35–42

    PubMed  Article  Google Scholar 

  46. Schmader KE (2002) Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 18(6):350–354

    PubMed  Article  Google Scholar 

  47. Galer BS, Gianas A, Jensen MP (2000) Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 47(2):123–128

    CAS  PubMed  Article  Google Scholar 

  48. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai K-S, Stacey B (2005) Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manag 30(4):374–385

    Article  Google Scholar 

  49. Benbow S, Wallymahmed M, MacFarlane I (1998) Diabetic peripheral neuropathy and quality of life. QJM: monthly journal of the. Assoc Physicians 91(11):733–737

    CAS  Google Scholar 

  50. Cherif F, Zouari HG, Cherif W, Hadded M, Cheour M, Damak R (2020) Depression prevalence in neuropathic pain and its impact on the quality of life. Pain Res Manag 2020

  51. Moghaddam JF, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A (2012) Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P). Sleep Breath 16(1):79–82

    Article  Google Scholar 

  52. Artner J, Cakir B, Spiekermann J-A, Kurz S, Leucht F, Reichel H et al (2013) Prevalence of sleep deprivation in patients with chronic neck and back pain: a retrospective evaluation of 1016 patients. J Pain Res 6:1

    PubMed  Google Scholar 

  53. Cheatle MD, Foster S, Pinkett A, Lesneski M, Qu D, Dhingra L (2016) Assessing and managing sleep disturbance in patients with chronic pain. Anesthesiol Clin 34(2):379–393

    PubMed  Article  Google Scholar 

  54. Davoudi M, Rezaei P, Rajaeiramsheh F, Ahmadi SM, Taheri AA (2021) Predicting the quality of life based on pain dimensions and psychiatric symptoms in patients with Painful diabetic neuropathy: a cross-sectional prevalence study in Iranian patients. Health Qual Life Outcomes. 19(1):49. https://doi.org/10.1186/s12955-021-01697-w.

  55. Ding X, Fang C, Li X, Cao Y-J, Zhang Q-L, Huang Y et al (2019) Type 1 diabetes-associated cognitive impairment and diabetic peripheral neuropathy in Chinese adults: results from a prospective cross-sectional study. BMC Endocr Disord 19(1):1–6

    Article  Google Scholar 

  56. Naranjo C, Ortega-Jiménez P, Del Reguero L, Moratalla G, Failde I (2020) Relationship between diabetic neuropathic pain and comorbidity. Their impact on pain intensity, diabetes complications and quality of life in patients with type-2 diabetes mellitus. Diabetes Res Clin Pract 165:108236

    PubMed  Article  Google Scholar 

  57. Selvarajah D, Wilkinson I, Emery C, Shaw P, Griffiths P, Gandhi R et al (2008) Thalamic neuronal dysfunction and chronic sensorimotor distal symmetrical polyneuropathy in patients with type 1 diabetes mellitus. Diabetologia. 51(11):2088–2092

    CAS  PubMed  Article  Google Scholar 

  58. Selvarajah D, Wilkinson ID, Gandhi R, Griffiths PD, Tesfaye S (2011) Microvascular perfusion abnormalities of the Thalamus in painful but not painless diabetic polyneuropathy: a clue to the pathogenesis of pain in type 1 diabetes. Diabetes Care 34(3):718–720

    PubMed  PubMed Central  Article  Google Scholar 

  59. Northam EA, Rankins D, Lin A, Wellard RM, Pell GS, Finch SJ et al (2009) Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care 32(3):445–450

    PubMed  PubMed Central  Article  Google Scholar 

  60. Zilliox LA, Chadrasekaran K, Kwan JY, Russell JW (2016) Diabetes and cognitive impairment. Curr Diabetes Rep 16(9):87

    Article  CAS  Google Scholar 

  61. Cerezo-Huerta K, Yáñez-Téllez G, Aguilar-Salinas CA (2019) Funcionamiento ejecutivo y Artículo original adherencia terapéutica en la diabetes mellitus tipo 2. Archivos de Neurociencias 23(3):42–53

    Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

Authors

Contributions

NA, RG, and AF recruited the participants, analyzed and interpreted the data, and were the contributors to writing the manuscript. NA, RG, and AF revised the data interpretation, read, and approved the final manuscript. AF helped in the data entry and analyzed and generated the result sheets. The authors have read and approved the manuscript.

Corresponding author

Correspondence to Romany H. Gabra.

Ethics declarations

Ethics approval and consent to participate

The protocol and study design were approved by the local ethical committee in the Faculty of Medicine, Assiut University, Egypt (IRB17100291). An informed signed consent was obtained from all participants.

Consent for publication

All the participants’ consent for publication was obtained.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abo-Elfetoh, N.M., Farag, A.I. & Gabra, R.H. Impact of pain severity on functioning domains, sleep, and cognition in painful diabetic peripheral polyneuropathy patients. Middle East Curr Psychiatry 29, 83 (2022). https://doi.org/10.1186/s43045-022-00243-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43045-022-00243-8

Keywords

  • Painful diabetic peripheral polyneuropathy (PDPN)
  • Functioning domains
  • Sleep quality
  • Brief pain inventory short form
  • Pain visual analog scale
  • Cognitive function